Lactoferrin: A Modulator for Immunity against Tuberculosis Related Granulomatous Pathology

There is great need for a therapeutic that would limit tuberculosis related pathology and thus curtail spread of disease between individuals by establishing a “firebreak” to slow transmission. A promising avenue to increase current therapeutic efficacy may be through incorporation of adjunct compone...

Full description

Saved in:
Bibliographic Details
Main Author: Jeffrey K. Actor
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2015/409596
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832563249790320640
author Jeffrey K. Actor
author_facet Jeffrey K. Actor
author_sort Jeffrey K. Actor
collection DOAJ
description There is great need for a therapeutic that would limit tuberculosis related pathology and thus curtail spread of disease between individuals by establishing a “firebreak” to slow transmission. A promising avenue to increase current therapeutic efficacy may be through incorporation of adjunct components that slow or stop development of aggressive destructive pulmonary pathology. Lactoferrin, an iron-binding glycoprotein found in mucosal secretions and granules of neutrophils, is just such a potential adjunct therapeutic agent. The focus of this review is to explore the utility of lactoferrin to serve as a therapeutic tool to investigate “disruption” of the mycobacterial granuloma. Proposed concepts for mechanisms underlying lactoferrin efficacy to control immunopathology are supported by data generated based on in vivo models using nonpathogenic trehalose 6,6′-dimycolate (TDM, cord factor).
format Article
id doaj-art-dc6a351c038b4b79abc6d32589dc65d7
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-dc6a351c038b4b79abc6d32589dc65d72025-02-03T01:20:39ZengWileyMediators of Inflammation0962-93511466-18612015-01-01201510.1155/2015/409596409596Lactoferrin: A Modulator for Immunity against Tuberculosis Related Granulomatous PathologyJeffrey K. Actor0UTHealth, Department of Pathology, University of Texas-Houston Medical School, Houston, TX 77030, USAThere is great need for a therapeutic that would limit tuberculosis related pathology and thus curtail spread of disease between individuals by establishing a “firebreak” to slow transmission. A promising avenue to increase current therapeutic efficacy may be through incorporation of adjunct components that slow or stop development of aggressive destructive pulmonary pathology. Lactoferrin, an iron-binding glycoprotein found in mucosal secretions and granules of neutrophils, is just such a potential adjunct therapeutic agent. The focus of this review is to explore the utility of lactoferrin to serve as a therapeutic tool to investigate “disruption” of the mycobacterial granuloma. Proposed concepts for mechanisms underlying lactoferrin efficacy to control immunopathology are supported by data generated based on in vivo models using nonpathogenic trehalose 6,6′-dimycolate (TDM, cord factor).http://dx.doi.org/10.1155/2015/409596
spellingShingle Jeffrey K. Actor
Lactoferrin: A Modulator for Immunity against Tuberculosis Related Granulomatous Pathology
Mediators of Inflammation
title Lactoferrin: A Modulator for Immunity against Tuberculosis Related Granulomatous Pathology
title_full Lactoferrin: A Modulator for Immunity against Tuberculosis Related Granulomatous Pathology
title_fullStr Lactoferrin: A Modulator for Immunity against Tuberculosis Related Granulomatous Pathology
title_full_unstemmed Lactoferrin: A Modulator for Immunity against Tuberculosis Related Granulomatous Pathology
title_short Lactoferrin: A Modulator for Immunity against Tuberculosis Related Granulomatous Pathology
title_sort lactoferrin a modulator for immunity against tuberculosis related granulomatous pathology
url http://dx.doi.org/10.1155/2015/409596
work_keys_str_mv AT jeffreykactor lactoferrinamodulatorforimmunityagainsttuberculosisrelatedgranulomatouspathology